Xencor: Strong Buy, XmAb819 Presentation, And End Of 2026 XmAb942 Interim Data

Xencor remains a Strong Buy, driven by pipeline progress in oncology and inflammatory disorders. XmAb819 demonstrated a 25% response rate and 70% disease control in heavily pre-treated ccRCC patients; pivotal study initiation is targeted for 2027. XmAb942, a next-gen anti-TL1A for ulcerative colitis, is differentiated by extended dosing and superior TL1A inhibition; interim phase 2b data are expected by the end of 2026. XNCR maintains a robust cash position ($541.8M as of March 2026), funding operations into mid-2028, but may raise additional capital via shelf registration.